Primary Care

Taking simvastatin in the morning compared with in the evening: randomised controlled trial

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7418.788 (Published 02 October 2003) Cite this as: BMJ 2003;327:788

Serum cholesterol - a surrogate outcome

Whether
statins should be given in the evening or in the morning,1 if at all,
depends on whether it is advisable to lower cholesterol as much or as little as
possible. There is much evidence for the latter, because in all clinical2,3
and angiographic4 trials, where dose-response was calculated, the
outcome was independent on the degree of cholesterol lowering, indicating that
the effect of the statins is due to other mechanisms. In favour of the latter
view is also that in almost all cohort studies of old people high cholesterol
was not a risk factor for coronary5-10 or total5,7,11-13
mortality and has even been associated with longevity,10,14-17 and,
in Russia, with cardiovascular health.18 These findings have been
ignored or belittled as minor aberrations from the LDL receptor hypothesis, but
considering that more than 90 per cent of all cardiovascular disease occur in
people above age 60, it is in fact one of the most serious blows against it. Why
should we lower cholesterol if a high cholesterol is unimportant or beneficial?

    
It may be fruitful to search for a drug with the same effects on the
cardiovascular system as the statins but without influencing cholesterol
synthesis. In the meantime it seems worth while to test the lowest, effective
statin dose instead of trying to lower cholesterol as much as possible.

 

  1. Wallace
    A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the
    evening: randomised controlled trial. BMJ 2003; 327: 788 [Full
    text]
  2. Sacks
    FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald
    E. Relationship between plasma LDL concentrations during treatment with
    pravastatin and recurrent coronary events in the cholesterol and recurrent
    events trial. Circulation. 1998; 97: 1446-52 [Full
    Text]
  3. Schwartz
    GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman
    BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive
    Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin
    on early recurrent ischemic events in acute coronary syndromes: the MIRACL
    study: a randomized controlled trial.
    JAMA
    2001; 285:1711-8.
    [Pub
    Med]
  4. Ravnskov
    U. Is atherosclerosis caused by high cholesterol? QJM2002; 95:
    397-403. [Full
    text]
  5. Siegel
    D, Kuller L, Lazarus NB, Black D, Feigal D, Hughes G, Schoenberger JA,
    Hulley SB. Predictors of cardiovascular events and mortality in the Systolic
    Hypertension in the Elderly Program pilot project.
    Am
    J Epidemiol 1987; 126:385-9.
    [PubMed]
  6. Nissinen
    A, Pekkanen J, Porath A, Punsar S, Karvonen MJ. Risk factors for
    cardiovascular disease among 55 to 74 year-old Finnish men: a 10-year
    follow-up.
    Ann Med1989; 21:239-40.
    [PubMed]
  7. Krumholz
    HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI,
    Tsukahara R, Ostfeld AM, Berkman LF.
    Lack
    of association between cholesterol and coronary heart disease mortality and
    morbidity and all-cause mortality in persons older than 70 years.
    JAMA 1994; 272: 1335-40 [Pub
    Med]
  8. Weijenberg
    MP, Feskens EJ, Bowles CH, Kromhout D.
    Serum total cholesterol and systolic blood
    pressure as risk factors for mortality from ischemic heart disease among
    elderly men and women.
    J
    Clin Epidemiol1994; 47:197-205.
    [PubMed].
  9. Simons
    LA, McCallum J, Friedlander Y, Simons J. Diabetes, mortality and coronary
    heart disease in the prospective Dubbo study of Australian elderly.
    Aust
    N Z J Med1996; 26:66-74.
    [PubMed]
  10. Räihä
    I, Marniemi J, Puukka P, Toikka T, Ehnholm C, Sourander L. Effect of serum
    lipids, lipoproteins, and apolipoproteins on vascular and nonvascular
    mortality in the elderly.
    Arterioscler Thromb Vasc
    Biol1997; 17:1224-32. [Full
    Text]
  11. Zimetbaum
    P, Frishman WH, Ooi WL, Derman MP, Aronson M, Gidez LI, Eder HA. Plasma
    lipids and lipoproteins and the incidence of cardiovascular disease in the
    very elderly. The Bronx aging study. Arterioscl Thromb1992; 12:
    416-423. [Pub
    Med]
  12. Fried
    LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, Robbins JA,
    Gardin JM.  Risk factors for
    5-year mortality in older adults: the Cardiovascular Health Study. JAMA
    1998; 279:585-92.
    [PubMed]
  13. Chyou
    PH, Eaker ED.
    Serum cholesterol concentrations and
    all-cause mortality in older people. Age Ageing 2000; 29:69-74. [Full
    Text]
  14. Forette
    B, Tortrat D, Wolmark Y. Cholesterol as risk factor for mortality in elderly
    women.
    Lancet
    1989; 1:868-70.
    [Pub
    Med]
  15. Weverling-Rijnsburger
    AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total
    cholesterol and risk of mortality in the oldest old. Lancet 1997;
    350:1119-23. [PubMed]
  16. Jonsson
    A, Sigvaldason H, Sigfusson N. Total cholesterol and mortality after age 80
    years. Lancet1997;  350:1778-9.
  17. Schatz
    IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and
    all-cause mortality in elderly people from the Honolulu Heart Program: a
    cohort study.
    Lancet
    2001; 358:351-5.
    [Pub
    Med]
  18. Shestov
    DB, Deev AD, Klimov AN, Davis CE, Tyroler HA. Increased risk of coronary
    heart disease death in men with low total and low-density lipoprotein
    cholesterol in the Russian Lipid Research Clinics Prevalence Follow-up Study.
    Circulation 1993; 88:846-53. [Pub
    Med]

 

 

 

Competing interests:  
None declared

Competing interests: No competing interests

06 October 2003
Uffe Ravnskov
Independent researcher
Magle Stora Kyrkogata 9, S-22350 Lund, Sweden